Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temelimab for neuropsychiatric symptoms in post-COVID-19 syndrome
2022-000618-32Phase 2Completed
- Sponsor
- GeNeuro
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of temelimab in post-COVID syndrome (2 arms), sponsored by GeNeuro. Primary endpoint: Improvement in cognitive impairment or fatigue at 6 months. Started Jul 2022; status: completed.
02
Drugs
temelimab
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2022-000618-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000618-32.